Bill > SB120

This bill requires health insurance plans in Delaware to provide coverage for biomarker testing, which is a sophisticated medical diagnostic method that analyzes an individual's tissue, blood, or other biospecimens to identify characteristics that indicate biological processes, disease progression, or potential responses to specific medical treatments. The bill defines biomarkers as objectively measurable indicators that can include gene mutations, genetic characteristics, and protein expressions. Coverage would be mandated for individual, group, state employee, and public assistance insurance plans when the testing is supported by medical and scientific evidence, such as FDA-approved test indications, drug-related recommendations, Medicare coverage determinations, and nationally recognized clinical practice guidelines. Insurers must provide this coverage in a way that minimizes patient care disruptions, like reducing the need for multiple biopsies. The bill specifically excludes certain limited benefit health insurance policies from these requirements and will apply to all policies issued or renewed after December 31, 2026. The legislation aims to ensure patients have access to advanced diagnostic tools that can help personalize and improve medical treatment across various health conditions.

Business and Industry

https://legis.delaware.gov/BillDetail?LegislationId=142167